Beyond Air Sets June 26 for Fiscal Year End 2026 Earnings Call
Event summary
- Beyond Air (NASDAQ: XAIR) will report fiscal Q4 and full-year 2026 results on June 26, 2026.
- Conference call scheduled for 8:00 AM ET the same day.
- Company focuses on nitric oxide therapies for respiratory, neurological disorders, and solid tumors.
- FDA-approved LungFit PH system targets neonatal hypoxic respiratory failure.
The big picture
Beyond Air operates in the competitive medical device and biopharmaceutical space, where nitric oxide therapies represent a niche but growing segment. The company's FDA approval for LungFit PH positions it as a player in neonatal respiratory care, though scaling commercial adoption remains critical. Investors will watch for signs of broader pipeline development beyond its current product.
What we're watching
- Commercial Execution
- How Beyond Air will scale its FDA-approved LungFit PH system in the neonatal respiratory failure market.
- Pipeline Progress
- Whether the company can advance additional nitric oxide-based therapies beyond its current approvals.
- Financial Performance
- The pace at which Beyond Air achieves revenue growth and cost management in fiscal 2026.
Related topics